DEEPSONBIO CO.KR
Head Office | 305-53, 3rd floor, 10, Chunghon-gil, Chuncheon-si, Gangwon-do, Republic of Korea TEL. 82-31-713-5450
R&D Center | Seoul National University Bundang Hospital Healthcare Innovation Partk 6F, 172,
Dolma-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea TEL.82-31-713-5450
Business registration number | 423-86-01190
Deepson Bio introduced the dementia electronic drug " Neuclare (therapeutic Ultrasound)," which complements the side effects of invasive treatment (injection) by other companies. It is characterized by the use of ultrasonic waves rather than injections. Through this, it induces the release of 'amyloid beta', a dementia-causing substance accumulated in the brain.
2025/03/19
Maeil Business
기사바로가기:
https://www.mk.co.kr/en/economy/11268179(ENG)
https://www.mk.co.kr/news/economy/11268179 (KOR)